Kalamazoo Resources led materials sector gainers this morning as the release of drill assays from its Mallina West gold ...

The advent of a Trump presidency is accelerating a divergence on digital currencies between the world’s two largest economies ...

After the benchmark S&P/ASX 200 surged 7.5 per cent in 2024, investors are looking to see where the growth will come from in ...

Cell therapies have suffered from hyped-up expectations, clinical setbacks and high costs. But maybe, just maybe, Arovella is ...

ASX tech rocked a 50pc gain in 2024, Archer Materials shone in December, and Dubber and Brainchip cashed in on major ...

Opyl has entered a joint venture with X Firm to market its TrialKey platform in key markets, while Dimerix has inked another ...

Special Report: James Bay Minerals is progressing exploration at its Independence gold project in Lander County, Nevada, with ...

Riversgold’s (ASX:RGL) rock chip sampling is defining multiple multi-metal targets across the ~25 km strike of the Saint John ...

ASX climbs while Bitcoin surges past US$102k thanks to Trump’s crypto push and Capricorn hits a gold output record.

ASX 200 edges up on a tech rally, while miners struggle, Barrick Gold threatens a Mali shutdown, and Bitcoin bounces back.

Fraser Palamara details Dimerix's (ASX:DXB) deal with Japanese pharmaceutical company FUSO to fight a deadly kidney disease.

Stockhead's Sarah Hughan unpacks clinical stage biotech company AdAlta, set to unlock value from its AD-214 asset and expand its pipeline through its "East to West" cell therapy strategy in 2025.